After 28 Years, Professor David Y. Graham Says Goodbye and Helicobacter Welcomes a New Editor
Helicobacter
by David Y. Graham
2d ago
Helicobacter, Volume 29, Issue 3, May/June 2024 ..read more
Visit website
Family‐based Helicobacter pylori infection control and management strategy and screen‐and‐treat strategy are highly cost‐effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level
Helicobacter
by Chen Zhang, Ya‐Bin Qi, Ruo‐Bing Hu, Lu Xu, Xiao‐Ting Li, Jing Ma, Qiao‐Qiao Shao, Mohammed Awadh Abdun, Ishtiaq Ur Rahman, Wen‐Jun Shi, Fu‐Qiang Li, Jian‐Jie Yu, Ming‐Kai Yuan, Qi Chen, Hong Lu, Song‐Ze Ding
5d ago
Abstract Background The overall benefits of the newly introduced family-based Helicobacter pylori (H. pylori) infection control and management (FBCM) and screen-and-treat strategies in preventing multiple upper gastrointestinal diseases at national level in China have not been explored. We investigate the cost-effectiveness of these strategies in the whole Chinese population. Materials and Methods Decision trees and Markov models of H. pylori infection-related non-ulcer dyspepsia (NUD), peptic ulcer disease (PUD), and gastric cancer (GC) were developed to simulate the cost-effectiveness of the ..read more
Visit website
Efficacy of Tetracycline Three Times Daily was Comparable to That of Four Times Daily for Helicobacter pylori Rescue Treatment: A Multicenter, Noninferiority, Randomized Controlled Trial
Helicobacter
by Zhongxue Han, Qiumei Zhang, Iqtida Ahmed Mirza, Yuming Ding, Xueping Nan, Qing Zhao, Ruili Li, Lidong Xu, Ning Zhang, Miao Duan, Shuyan Zeng, Qingzhou Kong, Wenlin Zhang, Hui Wang, Xiaoqi Wu, Xiuli Zuo, Yanqing Li, Yueyue Li
5d ago
ABSTRACT Background The optimal dosage of tetracycline remains unclear for Helicobacter pylori eradication. Frequent dosing requirements may decrease patient adherence and increase the incidence of adverse events, potentially reducing treatment efficacy. This study aimed to compare the efficacy of different tetracycline dosages in rescue treatment for H. pylori infection. Methods A total of 406 patients needing H. pylori rescue treatment were enrolled. Patients were randomized into two groups and received bismuth-containing quadruple therapies as follows: esomeprazole 40 mg twice daily, bismut ..read more
Visit website
Helicobacter pylori CagA Promotes the Formation of Gallstones by Increasing the Permeability of Gallbladder Epithelial Cells
Helicobacter
by Jingjing Yu, Yuanhang He, Wenchao Yao, Tianming Liu, Xuxu Liu, Yi Zheng, Chenjun Hao, Dongbo Xue
5d ago
ABSTRACT Background The formation of gallstones is often accompanied by chronic inflammation, and the mechanisms underlying inflammation and stone formation are not fully understood. Our aim is to utilize single-cell transcriptomics, bulk transcriptomics, and microbiome data to explore key pathogenic bacteria that may contribute to chronic inflammation and gallstone formation, as well as their associated mechanisms. Methods scRNA-seq data from a gallstone mouse model were extracted from the Gene Expression Omnibus (GEO) database and analyzed using the FindCluster() package for cell clustering ..read more
Visit website
Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial
Helicobacter
by Qingzhou Kong, Iqtida Ahmed Mirza, Xiaoqian Zhang, Xiaohui Song, Xiaowei Li, Qiumei Zhang, Lidong Xu, Yuting Guo, Yanan Yu, Xiuli Zuo, Yanqing Li, Yueyue Li
1w ago
ABSTRACT Background Potassium-competitive acid blockers have demonstrated enormous potential in the eradication treatment of Helicobacter pylori infection, with tegoprazan being one of the representatives. The available data on the safety and efficacy of tegoprazan in dual therapy are limited. Materials and Methods The multicenter, noninferiority, randomized-controlled trial was conducted from May 2023 to March 2024. Treatment-naive subjects were randomly assigned (1:1) to enter either the tegoprazan–amoxicillin (TA) group (tegoprazan 50 mg twice daily and amoxicillin 750 mg four times daily ..read more
Visit website
CCR6+ T helper cells and regulatory T cells in the blood and gastric mucosa during Helicobacter pylori infection
Helicobacter
by Vladimir Talayev, Maria Svetlova, Irina Zaichenko, Elena Voronina, Olga Babaykina, Natalia Neumoina, Ksenia Perfilova
2w ago
Abstract Background Helicobacter pylori (H. pylori) can evade the host's immune response and persist for a long time on the gastric mucosa. T helper (Th) cells appear to be involved in the control of H. pylori bacteria but promote mucosal inflammation. In contrast, regulatory T cells (Tregs) may reduce inflammation but promote H. pylori persistence. CC motif chemokine receptor 6 (CCR6) is involved in the migration of various cells into inflamed gastric mucosa. In this study, we examined CCR6+ Th cells and CCR6+ Tregs during H. pylori infection in humans. Materials and Methods Isolation of cell ..read more
Visit website
Prevalence of multidrug‐resistant Campylobacter species in wastewater effluents: A menace of environmental and public health concern
Helicobacter
by Olufunmilayo Modupe Oluwakoya, Anthony Ifeanyi Okoh
3w ago
Abstract The prevalence of multidrug-resistant Campylobacter species in wastewater effluents presents a formidable challenge at the intersection of environmental sustainability and public health. This study examined the presence of multidrug-resistant Campylobacter in wastewater effluents in the Eastern Cape Province, South Africa, and its implications for environmental ecosystems and public health. Forty-five samples from household effluent (HHE) and wastewater treatment plant effluent (WWTPE) were collected at different geographical locations within the province between April and September 2 ..read more
Visit website
Vonoprazan‐based therapies versus PPI‐based therapies in patients with H. pylori infection: Systematic review and meta‐analyses of randomized controlled trials
Helicobacter
by Ligang Liu, Hekai Shi, Yufei Shi, Anlin Wang, Nuojin Guo, Fang Li, Milap C. Nahata
3w ago
Abstract Background This study aims to evaluate the efficacy and safety of vonoprazan-amoxicillin (VA), vonoprazan-amoxicillin-clarithromycin (VAC), vonoprazan-based bismuth-containing quadruple therapy (VBQT), and PPI-based triple (PAC) or quadruple therapy (PBQT) for H. pylori infection with the consideration of duration of therapy and amoxicillin dose (H: high; L: low). Materials and Methods PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched for eligible randomized controlled trials (RCTs) up to December 15, 2023. The efficacy outcome was eradication rate ..read more
Visit website
Nationwide survey of Helicobacter pylori seropositivity and gastric atrophy in Zambia
Helicobacter
by Violet Kayamba, Husna Munshi, Mutinta Nyama Hankolwe, Ciluvya Kaluba Kavimba, Gershom Chongwe, Viktoria Knaze, Jin Young Park, Paul Kelly
3w ago
Abstract Background Helicobacter pylori (H. pylori) is a common bacterial infection which predominately drives upper gastrointestinal pathology. We carried out a nationwide serological survey in response to the deficiency of robust African data on H. pylori prevalence, age of acquisition, socio-geographic determinants, and impact on gastric physiology. Materials and Methods This was a cross-sectional study of archival plasma samples collected during the Zambia Population-based HIV impact Assessment (ZAMPHIA) 2016 survey. ZAMPHIA used a two-stage door-to-door stratified cluster sample approach ..read more
Visit website
Helicobacter pylori infection found during upper endoscopy performed for the diagnosis of celiac, inflammatory bowel diseases, and eosinophilic esophagitis: A multicenter pediatric European study
Helicobacter
by Kallirroi Kotilea, Claudio Romano, Erasmo Miele, Angelika Kindermann, Yael Dolstra, Zrinjka Misak, Vaidotas Urbonas, Josef Sykora, Pedro Urruzuno, Alexander Krauthammer, Maria Rogalidou, Konstantina Dimakou, Tsili Zangen, Eleftheria Roma, Aglaia Zellos, María Luz Cilleruelo, Meline M'Rini, Patrick Bontems, Yasin Sahin, Marta Tavares, Tatevik Shahinyan, Biljana Vuletic, Nicolas Kalach, Michal Kori, the ESPGHAN H. pylori special interest group
3w ago
Abstract Background Helicobacter pylori may be found during upper gastrointestinal endoscopy (UGE) performed to diagnose celiac disease (CeD), inflammatory bowel disease (IBD), and eosinophilic esophagitis (EoE). We aimed to describe the frequency of H. pylori in children undergoing UGE for CeD, IBD, and EoE and the number of children receiving eradication treatment. Materials and Methods A retrospective multicenter study from 14 countries included pediatric patients diagnosed with CeD, IBD, and EoE between January 2019 and December 2021. Data collected: age, gender, hematologic parameters, en ..read more
Visit website

Follow Helicobacter on FeedSpot

Continue with Google
Continue with Apple
OR